156 related articles for article (PubMed ID: 34968491)
1. The potential value of amlexanox in the treatment of cancer: Molecular targets and therapeutic perspectives.
Bailly C
Biochem Pharmacol; 2022 Mar; 197():114895. PubMed ID: 34968491
[TBL] [Abstract][Full Text] [Related]
2. Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling.
Cheng C; Ji Z; Sheng Y; Wang J; Sun Y; Zhao H; Li X; Wang X; He Y; Yao J; Wang L; Zhang C; Guo Y; Zhang J; Gao WQ; Zhu HH
Theranostics; 2018; 8(17):4633-4648. PubMed ID: 30279728
[TBL] [Abstract][Full Text] [Related]
3. An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice.
Reilly SM; Chiang SH; Decker SJ; Chang L; Uhm M; Larsen MJ; Rubin JR; Mowers J; White NM; Hochberg I; Downes M; Yu RT; Liddle C; Evans RM; Oh D; Li P; Olefsky JM; Saltiel AR
Nat Med; 2013 Mar; 19(3):313-21. PubMed ID: 23396211
[TBL] [Abstract][Full Text] [Related]
4. The role of TBK1 in cancer pathogenesis and anticancer immunity.
Runde AP; Mack R; S J PB; Zhang J
J Exp Clin Cancer Res; 2022 Apr; 41(1):135. PubMed ID: 35395857
[TBL] [Abstract][Full Text] [Related]
5. Amlexanox Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss.
Zhang Y; Guan H; Li J; Fang Z; Chen W; Li F
Sci Rep; 2015 Sep; 5():13575. PubMed ID: 26338477
[TBL] [Abstract][Full Text] [Related]
6. Dual TBK1/IKKε inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro.
Zhou Z; Qi J; Lim CW; Kim JW; Kim B
Toxicology; 2020 Nov; 444():152579. PubMed ID: 32905826
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of TBK1 by amlexanox attenuates paraquat-induced acute lung injury.
Wang N; Li Y; Wang X; Ma Z; Wang Y; Zhang C; Yuan Y; Zhao M
Toxicology; 2020 Oct; 443():152555. PubMed ID: 32763286
[TBL] [Abstract][Full Text] [Related]
8. Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction.
Cruz VH; Arner EN; Wynne KW; Scherer PE; Brekken RA
Mol Metab; 2018 Oct; 16():139-149. PubMed ID: 29935921
[TBL] [Abstract][Full Text] [Related]
9. Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKK
Beyett TS; Gan X; Reilly SM; Chang L; Gomez AV; Saltiel AR; Showalter HD; Tesmer JJG
Mol Pharmacol; 2018 Oct; 94(4):1210-1219. PubMed ID: 30082428
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of amlexanox as a G protein-coupled receptor kinase 5 inhibitor.
Homan KT; Wu E; Cannavo A; Koch WJ; Tesmer JJ
Molecules; 2014 Oct; 19(10):16937-49. PubMed ID: 25340299
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of TANK-binding kinase signaling towards anticancer drug development: Challenges and opportunities.
Alam M; Ansari MM; Noor S; Mohammad T; Hasan GM; Kazim SN; Hassan MI
Int J Biol Macromol; 2022 May; 207():1022-1037. PubMed ID: 35358582
[TBL] [Abstract][Full Text] [Related]
12. Amlexanox exerts anti-inflammatory actions by targeting phosphodiesterase 4B in lipopolysaccharide-activated macrophages.
Han Y; Hou R; Zhang X; Liu H; Gao Y; Li X; Qi R; Cai R; Qi Y
Biochim Biophys Acta Mol Cell Res; 2020 Oct; 1867(10):118766. PubMed ID: 32504661
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer.
Bishop RT; Marino S; de Ridder D; Allen RJ; Lefley DV; Sims AH; Wang N; Ottewell PD; Idris AI
Cancer Lett; 2019 May; 450():76-87. PubMed ID: 30790681
[TBL] [Abstract][Full Text] [Related]
14. Non-canonical IKKs, IKKϵ and TBK1, as novel therapeutic targets in the treatment of non-small cell lung cancer.
Kim JY; Beg AA; Haura EB
Expert Opin Ther Targets; 2013 Oct; 17(10):1109-12. PubMed ID: 23984985
[TBL] [Abstract][Full Text] [Related]
15. Amlexanox ameliorates acetaminophen-induced acute liver injury by reducing oxidative stress in mice.
Qi J; Zhou Z; Lim CW; Kim JW; Kim B
Toxicol Appl Pharmacol; 2019 Dec; 385():114767. PubMed ID: 31697998
[TBL] [Abstract][Full Text] [Related]
16. Amlexanox: A Novel Therapeutic for Atopic, Metabolic, and Inflammatory Disease.
Dosanjh A; Won CY
Yale J Biol Med; 2020 Dec; 93(5):759-763. PubMed ID: 33380937
[TBL] [Abstract][Full Text] [Related]
17. A review on the role of TANK-binding kinase 1 signaling in cancer.
Alam M; Hasan GM; Hassan MI
Int J Biol Macromol; 2021 Jul; 183():2364-2375. PubMed ID: 34111484
[TBL] [Abstract][Full Text] [Related]
18. Acute TBK1/IKK-ε Inhibition Enhances the Generation of Disease-Associated Microglia-Like Phenotype Upon Cortical Stab-Wound Injury.
Rehman R; Tar L; Olamide AJ; Li Z; Kassubek J; Böckers T; Weishaupt J; Ludolph A; Wiesner D; Roselli F
Front Aging Neurosci; 2021; 13():684171. PubMed ID: 34326766
[TBL] [Abstract][Full Text] [Related]
19. Amlexanox Blocks the Interaction between S100A4 and Epidermal Growth Factor and Inhibits Cell Proliferation.
Cho CC; Chou RH; Yu C
PLoS One; 2016; 11(8):e0161663. PubMed ID: 27559743
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanism of inhibition of nonclassical FGF-1 export.
Rajalingam D; Kumar TK; Soldi R; Graziani I; Prudovsky I; Yu C
Biochemistry; 2005 Nov; 44(47):15472-9. PubMed ID: 16300395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
